Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

The candidate, which is still in early stages, targets the GLP-1, GIP and glucagon receptors. Novo’s blockbuster obesity and diabetes medications, Wegovy and Ozempic are GLP-1 receptor agonists, ...

In weight loss news, Novo Nordisk is paying China-based United Laboratories $200 million upfront to license a triple agonist of the GLP-1, GIP and glucagon receptors that could one day compete with ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, University of Tuebingen, Auf der Morgenstelle 8, Tuebingen 72076, Germany IFIT Cluster of Excellence EXC ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. Under the license agreement, Novo ...